Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial

被引：1

作者：

Ferguson, Gary T. ^{[1
]}

Rabe, Klaus F. ^{[2
]}

Martinez, Fernando J. ^{[3
]}

Wang, Chen ^{[4
]}

Singh, Dave ^{[5
]}

Wedzicha, Jadwiga A. ^{[6
]}

Trivedi, Roopa ^{[7
]}

St Rose, Earl ^{[8
]}

Ballal, Shaila ^{[8
]}

Mclaren, Julie ^{[9
]}

Darken, Patrick ^{[8
]}

Aurivillius, Magnus ^{[10
]}

Reisner, Colin ^{[8
]}

Dorinsky, Paul ^{[7
]}

机构：

[1] Pulm Res Inst Southeast Michigan, Farmington Hills, MI USA

[2] Albrechts Univ Kiel, Airway Res Ctr North, LungenClin Grosshansdorf & Christian, German Ctr Lung Res DZL, Grosshansdorf, Germany

[3] Weill Cornell Med, Joan & Sanford I Weill Dept Med, New York, NY USA

[4] China Japan Friendship Hosp, Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China

[5] Univ Manchester, Manchester Univ NHS Fdn Hosp Trust, Med Evaluat Unit, Manchester, Lancs, England

[6] Imperial Coll London, Natl Heart & Lung Inst, London, England

[7] AstraZeneca, Durham, NC USA

[8] AstraZeneca, Morristown, NJ USA

[9] AstraZeneca, Gaithersburg, MD USA

[10] AstraZeneca, Gothenburg, Sweden

来源：

EUROPEAN RESPIRATORY JOURNAL | 2020年 / 56卷

关键词：

COPD; -; management; exacerbations; Bronchodilators;

D O I：

10.1183/13993003.congress-2020.5238

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

5238

引用

页数：3

共 50 条

[1] Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial
Ferguson, G. T.
Rabe, K. F.
Martinez, F. J.
Wang, C.
Singh, D.
Wedzicha, J.
Trivedi, R.
Rose, E.
Ballal, S.
McLaren, J.
Darken, P.
Aurivillius, M.
Reisner, C.
Dorinsky, P.
PNEUMOLOGIE, 2021, 75 : S13 - S13
[2] COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels
Martinez, Fernando J.
Rabe, Klaus F.
Ferguson, Gary T.
Wang, Chen
Singh, Dave
Wedzicha, Jadwiga A.
Trivedi, Roopa
St Rose, Earl
Ballal, Shaila
Mclaren, Julie
Darken, Patrick
Aurivillius, Magnus
Reisner, Colin
Dorinsky, Paul
EUROPEAN RESPIRATORY JOURNAL, 2020, 56
[3] Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis
Rabe, Klaus F.
Martinez, Fernando J.
Ferguson, Gary T.
Wang, Chen
Singh, Dave
Wedzicha, Jadwiga A.
Trivedi, Roopa
St Rose, Earl
Ballal, Shaila
Mclaren, Julie
Darken, Patrick
Aurivillius, Magnus
Reisner, Colin
Dorinsky, Paul
EUROPEAN RESPIRATORY JOURNAL, 2020, 56
[4] Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis
Rabe, K. F.
Martinez, F. J.
Ferguson, G. T.
Wang, C.
Singh, D.
Wedzicha, J.
Trivedi, R.
Rose, E.
Ballal, S.
McLaren, J.
Darken, P.
Aurivillius, M.
Reisner, C.
Dorinsky, P.
PNEUMOLOGIE, 2021, 75 : S12 - S12
[5] Single-Inhaler Triple Combination Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) at Two Corticosteroid Dose Levels in COPD: ETHOS Trial
Rabe, K. F.
Martinez, F. J.
Ferguson, G. T.
Wang, C.
Singh, D.
Wedzicha, J. A.
Trivedi, R.
St Rose, E.
Ballal, S.
McLaren, J.
Darken, P.
Aurivillius, M.
Reisner, C.
Dorinsky, P.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[6] COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS
Rabe, Klaus F.
Martinez, Fernando J.
Ferguson, Gary T.
Singh, Dave
Wedzicha, Jadwiga A.
Jenkins, Martin
Aurivillius, Magnus
Reisner, Colin
Dorinsky, Paul
INTERNIST, 2021, 62 (SUPPL 2): : 181 - 181
[7] COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS
Rabe, K. F.
Martinez, F. J.
Ferguson, G. T.
Singh, D.
Wedzicha, J.
Jenkins, M.
Aurivillius, M.
Reisner, C.
Dorinsky, P.
PNEUMOLOGIE, 2021, 75 : S12 - S13
[8] Analysis of exacerbation rates by time interval post-randomization in the KRONOS Phase III study of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI)
Rabe, Klaus F.
Fabbri, Leonardo M.
Martinez, Fernando J.
Ferguson, Gary T.
Bourne, Eric
Ballal, Sheila
Darken, Patrick
Deangelis, Kiernan
Aurivillius, Magnus
Reisner, Colin
Dorinsky, Paul
EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[9] Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) on Symptoms and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the ETHOS Trial
Martinez, F. J.
Rabe, K. F.
Ferguson, G. T.
Wedzicha, J. A.
Trivedi, R.
St Rose, E.
Ballal, S.
Darken, P.
Aurivillius, M.
Dorinsky, P.
Reisner, C.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[10] Relative bioavailability of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) administered with and without a spacer in healthy adults
Dorinsky, Paul
Depetrillo, Paolo
Deangelis, Kiernan
Trivedi, Roopa
Mo, Mindy
Ballal, Shaila
Gillen, Michael
EUROPEAN RESPIRATORY JOURNAL, 2019, 54

← 1 2 3 4 5 →